[New targeted therapies in hormone-refractory prostate cancer].
Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is essentially unchanged. Effective treatments have not existed for prostate cancer progressing after androgen deprivation therapy until recently. Docetaxel based chemotherapy has demonstrated to extend patient survival in two large randomized studies. These studies have provided the impetus to combine docetaxel with novel biologic drugs to further consolidate the gains in long-term outcome. With the arrival of new therapies such as epothilone analogues, small molecule receptor tyrosine kinase inhibitors, monoclonal antibodies, bone-targeted drugs, antisense oligonucleotides, antiangiogenics drugs and endothelin receptor antagonists, the future of prostate cancer therapy appears promising.
Oudard
Stéphane
S
Département de cancérologie médicale, Hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris. stephane.oudard@egp.aphp.fr
Banu
Eugeniu
E
Scotte
Florian
F
Beuzeboc
Philippe
P
Guyader
Charlotte
C
Medioni
Jacques
J
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002117:Calcitriol / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D019332:Endothelin-1 / Q000037:antagonists & inhibitors; D034261:Epothilones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001897:Boronic Acids; D019496:Cancer Vaccines; D004164:Diphosphonates; D019332:Endothelin-1; D034261:Epothilones; D016376:Oligonucleotides, Antisense; D009944:Organoplatinum Compounds; D011480:Protease Inhibitors; D047428:Protein Kinase Inhibitors; D011719:Pyrazines; D043823:Taxoids; D000077143:Docetaxel; D000069286:Bortezomib; C081294:satraplatin; D002117:Calcitriol